Industry Trend Analysis - Autoimmune Developments Progress argenx Toward Profitability - DEC 2017
Western Europe October 2017 / Netherlands / Industry
argenx is progressing well with its lead candidate, with potential indications for three relatively minor but underserved autoimmune conditions looking likely. As a start-up company, success in...
Industry Trend Analysis - Trastuzumab Agreement A Defining Moment In Biosimilar Market Evolution - MAY 2017
Western Europe March 2017 / Netherlands / Industry
This settlement agreement represents a coming of age for the biosimilar market; whilst such agreements are common for simpler generics, this is the first time a major deal has been struck for a...
Industry Trend Analysis - Mylan's European Generic Sales On Course To Dominate In FY16 - NOV 2015
Western Europe October 2015 / Netherlands / Industry
Reflecting the results of the acquisition of Abbott's non-US generics businesses, Mylan's non-North America generic sales outstripped North American sales for the first time. The rate by which...
Industry Trend Analysis - Healthcare Market To Remain Competitive - AUG 2015
Western Europe July 2015 / Netherlands / Industry
The healthcare market in the Netherlands will continue to offer considerable commercial opportunities. As a part of the Health Insurance Act, implemented in 2006, private insurance for curative...
Industry Trend Analysis - Insurers Bargaining Power To Drive Down Drug Prices - DEC 2014
Western Europe October 2014 / Netherlands / Industry
The advent of health economics, coupled with increasing budget deficits, will result in more caps on medicine expenditure, especially on essential drugs - ultimately affecting patient access to...
Industry Trend Analysis - 2014 Will Be Tough For Drugmakers - JULY 2014
Western Europe June 2014 / Netherlands / Industry
Governments will increasingly impose price controls on pharmaceuticals. Drugmakers have generally charged what the market will bear in both developed and emerging markets. High prices were previous...
Industry Trend Analysis - Further Medicine Price Cuts Are Inevitable - APR 2014
Western Europe March 2014 / Netherlands / Industry
Despite expectations for a return to positive economic growth in 2014, the Dutch government will persist with austerity measures to comply with the EU's budget criteria. We therefore maintain that further restrictions on medicines prices under the Medicines Prices Act, which actually came into force long before the Eurozone debt crisis, will work to create a subdued outlook for patented and...
READ FULL ARTICLE
Industry Trend Analysis - EC Fines J&J/Novartis/Sandoz For Delaying Market Entry Of Generic Fentanyl - MAR 2014
Western Europe February 2014 / Netherlands / Industry
The European Commission's fines, totalling nearly EUR 16.3mn, levied against Johnson & Johnson and its subsidiary, Janssen-Cilag, and Novartis and its subsidiary, Sandoz, highlights the EC's emphas...
Industry Trend Analysis - Ageing Population Puts A Strain On Healthcare Expenditure - OCT 2013
Western Europe September 2013 / Netherlands / Industry
As the population of the Netherlands ages, the government will continue to face rising healthcare costs - especially as the growing number of elderly people among its population means...
Industry Trend Analysis - Political Dispute Focuses On Healthcare Insurance - FEB 2013
Western Europe January 2013 / Netherlands / Industry
BMI View: While the recently proposed healthcare cost-containment measures in the Netherlands do not include price cuts on medicines, we believe measures such as increased health insurance premiums...